Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease

International Journal of Medical Microbiology

Volumn 300, Issue 8, 2010, Pages 514-519

  Kahl, Barbara C ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chronic infection; Cystic fibrosis; Staphylococcus aureus

Indexed keywords

PANTON VALENTINE LEUKOCIDIN;

BACTERIAL COLONIZATION; BACTERIAL SINUSITIS; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG FIBROSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PATHOGENESIS; PERSISTENT INFECTION; PHENOTYPIC VARIATION; PREVALENCE; RESPIRATORY TRACT INFLAMMATION; SHORT SURVEY; STAPHYLOCOCCUS AUREUS;

COMMUNITY-ACQUIRED INFECTIONS; CYSTIC FIBROSIS; HUMANS; PNEUMONIA, STAPHYLOCOCCAL; PREVALENCE; STAPHYLOCOCCUS AUREUS;

EID: 78549246149     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2010.08.002     Document Type: Short Survey

References (54)

1. Armstrong D.S., Grimwood K., Carlin J.B., Carzino R., Gutierrez J.P., Hull J., Olinsky A., Phelan E.M., Robertson C.F., Phelan P.D. Lower airway inflammation in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 1997, 156:1197-1204.
2. Armstrong D.S., Hook S.M., Jamsen K.M., Nixon G.M., Carzino R., Carlin J.B., Robertson C.F., Grimwood K. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr. Pulmonol. 2005, 40:500-510.
3. Besier S., Smaczny C., von Mallinckrodt C., Krahl A., Ackermann H., Brade V., Wichelhaus T.A. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J. Clin. Microbiol. 2007, 45:168-172.
4. Bode L.G., Kluytmans J.A., Wertheim H.F., Bogaers D., Vandenbroucke-Grauls C.M., Roosendaal R., Troelstra A., Box A.T., Voss A., van der Tweel I., van Belkum A., Verbrugh H.A., Vos M.C. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N. Engl. J. Med. 2010, 362:9-17.
5. Branger C., Gardye C., Lambert-Zechovsky N. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J. Med. Microbiol. 1996, 45:294-301.
6. Bubeck W.J., Patel R.J., Schneewind O. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect. Immun. 2007, 75:1040-1044.
7. Cystic Fibrosis Foundation, 2008. Patient Registry. Annual Data Report. Bethesda, Maryland, USA.
8. Dasenbrook E.C., Merlo C.A., Diener-West M., Lechtzin N., Boyle M.P. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2008, 178:814-821.
9. Elizur A., Orscheln R.C., Ferkol T.W., Atkinson J.J., Dunne W.M., Buller R.S., Armstrong J.R., Mardis E.R., Storch G.A., Cannon C.L. Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 2007, 131:1718-1725.
10. Gillet Y., Issartel B., Vanhems P., Fournet J.C., Lina G., Bes M., Vandenesch F., Piemont Y., Brousse N., Floret D., Etienne J. Association between Staphylococcus aureus strains carrying gene for Panton-Valentin leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359:753-759.
11. Glikman D., Siegel J.D., David M.Z., Okoro N.M., Boyle-Vavra S., Dowell M.L., Daum R.S. Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S. aureus. Chest 2008, 133:1381-1387.
12. Goerke C., Kraning K., Stern M., Döring G., Botzenhart K., Wolz C. Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fibrosis patients. J. Infect. Dis. 2000, 181:984-989.
13. Gomez M.I., Lee A., Reddy B., Muir A., Soong G., Pitt A., Cheung A., Prince A. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat. Med. 2004, 10:842-848.
14. Goodrich J.S., Sutton-Shields T.N., Kerr A., Wedd J.P., Miller M.B., Gilligan P.H. Prevalence of community-associated methicillin-resistant Staphylococcus aureus in patients with cystic fibrosis. J. Clin. Microbiol. 2009, 47:1231-1233.
15. Kahl B., Herrmann M., Everding A., Koch H.G., Becker K., Harms E., Proctor R.A., Peters G. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J. Infect. Dis. 1998, 177:1023-1029.
16. Kahl B.C., Belling G., Becker P., Chatterjee I., Wardecki K., Hilgert K., Cheung A.L., Peters G., Herrmann M. Thymidine-dependent Staphylococcus aureus small colony variants (SCV) are associated with extensive changes in regulator and virulence gene expression profiles. Infect. Immun. 2005, 73:4119-4126.
17. Kahl B.C., Belling G., Reichelt R., Herrmann M., Proctor R.A., Peters G. Thymidine-dependent small-colony variants of Staphylococcus aureus exhibit gross morphological and ultrastructural changes consistent with impaired cell separation. J. Clin. Microbiol. 2003, 41:410-413.
18. Kahl B.C., Duebbers A., Lubritz G., Haeberle J., Koch H.G., Ritzerfeld B., Reilly M., Harms E., Proctor R.A., Herrmann M., Peters G. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J. Clin. Microbiol. 2003, 41:4424-4427.
19. Kluytmans J.A., Manders M.J., van Bommel E., Verbrugh H. Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect. Control. Hosp. Epidemiol. 1996, 17:793-797.
20. Kluytmans J.A., Mouton J.W., Ijzerman E.P., Vandenbroucke-Grauls C.A.W., Wagenvoort J.H., Verbrugh H.A. Nasal carriage of Staphylococcus aureus as a major risk factor of wound infections after cardiac surgery. J. Infect. Dis. 1995, 171:216-219.
21. Koulenti D., Lisboa T., Brun-Buisson C., Krueger W., Macor A., Sole-Violan J., Diaz E., Topeli A., DeWaele J., Carneiro A., Martin-Loeches I., Armaganidis A., Rello J. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit. Care Med. 2009, 37:2360-2368.
22. Labandeira-Rey M., Couzon F., Boisset S., Brown E.L., Bes M., Benito Y., Barbu E.M., Vazquez V., Hook M., Etienne J., Vandenesch F., Bowden M.G. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007, 315:1130-1133.
23. Lina G., Piemont Y., Godailt-Gamot F., Bes M., Peter M.O., Gauduchon V., Vandenesch F., Etienne J. Involvement of Panton-Valentin leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 1999, 29:1128-1132.
24. Lyczak J.B., Cannon C.L., Pier G.B. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 2002, 15:194-222.
25. Mainz J.G., Naehrlich L., Schien M., Käding M., Schiller I., Mayr S., Schneider G., Wiehlmann L., Cramer N., Pfister W., Kahl B.C., Beck J.F., Tümmler B. Concordant genotype of upper and lower airways P. aeruginosa and S. aureus isolates in cystic fibrosis. Thorax 2009, 64:535-540.
26. Mayer-Hamblett N., Aitken M.L., Accurso F.J., Kronmal R.A., Konstan M.W., Burns J.L., Sagel S.D., Ramsey B.W. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2007, 175:822-828.
27. Miall L.S., McGinley N.T., Brownlee K.G., Conway S.P. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch. Dis. Child. 2001, 84:160-162.
28. Muhlebach M.S., Miller M.B., Moore C., Wedd J.P., Drake A.F., Leigh M.W. Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis?. Pediatr. Pulmonol. 2006, 41:445-451.
29. Navarre W.W., Schneewind O. Surface proteins of gram-positive bacteria and mechanisms of their targeting to the cell wall envelope. Microbiol. Mol. Biol. Rev. 1999, 63:174-229.
30. Nouwen J., Boelens H., van Belkum A., Verbrugh H. Human factor in Staphylococcus aureus nasal carriage. Infect. Immun. 2004, 72:6685-6688.
31. Novick R.P., Ross H.F., Projan S.J., Kornblum J., Kreiswirth B.N., Moghazeh S. Synthesis of a staphylococcal virulence factor is controlled by a regulatory RNA molecule. EMBO 1993, 12:3967-3975.
32. Proctor R.A., von Eiff C., Kahl B.C., Becker K., Mc Namara P.J., Herrmann M., Peters G. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 2006, 4:295-305.
33. Ramsey B., Richardson M.A. Impact of sinusitis in cystic fibrosis. J. Allergy Clin. Immunol. 1992, 90:547-552.
34. Razvi S., Quittell L., Sewall A., Quinton H., Marshall B., Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009, 136:1554-1560.
35. Ren C.L., Morgan W.J., Konstan M.W., Schechter M.S., Wagener J.S., Fisher K.A., Regelmann W.E. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr. Pulmonol. 2007, 42:513-518.
36. Renders N.H., van Belkum A., Overbeek S.E., Mouton J.W., Verbrugh H.A. Molecular epidemiology of Staphylococcus aureus strains colonizing the lungs of related and unrelated cystic fibrosis patients. Clin. Microbiol. Infect. 1997, 3:216-221.
37. Ridder-Schaphorn S., Ratjen F., Dübbers A., Häberle J., Falk S., Küster P., Schuster A., Mellies U., Löwe B., Reintjes R., Peters G., Kahl B.C. Nasal Staphylococcus aureus carriage is not a risk factor for lower airway infection in young cystic fibrosis patients. J. Clin. Microbiol. 2007, 45:2979-2984.
38. Sagel S.D., Gibson R.L., Emerson J., McNamara S., Burns J.L., Wagener J.S., Ramsey B.W. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J. Pediatr. 2009, 154:183-188.
39. Saiman L. Microbiology of early CF lung disease. Paediatr. Respir. Rev. 2004, 5(Suppl. A):S367-S369.
40. Saiman L., Siegel J. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am. J. Infect. Control 2003, 31:S1-S62.
41. Sawicki G.S., Rasouliyan L., Pasta D.J., Regelmann W.E., Wagener J.S., Waltz D.A., Ren C.L. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 2008, 43:1117-1123.
42. Schneider M., Muhlemann K., Droz S., Couzinet S., Casaulta C., Zimmerli S. Clinical characteristics associated with isolation of small-colony variants of Staphylococcus aureus and Pseudomonas aeruginosa from respiratory secretions of patients with cystic fibrosis. J. Clin. Microbiol. 2008, 46:1832-1834.
43. Smyth A., Walters S., Smyth R. Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis. Thorax 2000, 55:251-252.
44. Souza H.A., Nogueira K.S., Matos A.P., Vieira R.P., Riedi C.A., Rosário N.A., Telles F.Q., Costa L.M. Early microbial colonization of cystic fibrosis patients identified by neonatal screening, with emphasis on Staphylococcus aureus. J. Pediatr. (Rio J.) 2006, 82:377-382.
45. Spicuzza L., Sciuto C., Vitaliti G., Di Dio G., Leonardi S., La Rosa M. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28:191-195.
46. Steinkamp G., Wiedemann B., Rietschel E., Krahl A., Gielen J., Barmeier H., Ratjen F. Prospective evaluation of emerging bacteria in cystic fibrosis. J. Cyst. Fibros. 2005, 4:41-48. Ermerging Bacteria Study Group.
47. Stone A., Quittell L., Zhou J., Alba L., Bhat M., Decelie-Germana J., Rajan S., Bonitz L., Welter J.J., Dozor A.J., Gherson I., Lowy F.D., Saiman L. Staphylococcus aureus nasal colonization among pediatric CF patients and their household contacts. Pediatr. Infect. Dis. J. 2009, 28:895-899.
48. Stone A., Saiman L. Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 2007, 13:515-521.
49. Szaff M., Høiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis. Acta Paediatr. Scand. 1982, 71:821-826.
50. Valenza G., Tappe D., Turnwald D., Frosch M., König C., Hebestreit H., Abele-Horn M. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J. Cyst. Fibros. 2008, 7:123-127.
51. Vandenesch F., Naimi T., Enright M.C., Lina G., Nimmo G.R., Heffernan H., Liassine N., Bes M., Greenland T., Reverdy M.-E., Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine Leukocidin genes: worldwide emergence. Emerg. Infect. Dis. 2003, 9:978-984.
52. von Eiff C., Becker K., Machka K., Stammer H., Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 2001, 344:11-16.
53. Wang R., Braughton K.R., Kretschmer D., Bach T.H., Queck S.Y., Li M., Kennedy A.D., Dorward D.W., Klebanoff S.J., Peschel A., Deleo F.R., Otto M. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 2007, 13:1510-1514.
54. Wiedemann B. Qualitätssicherung Mukoviszidose - Übersicht über den Gesundheitszustand der Patienten in Deutschland 2007 2008, Hippocampus, 80 pp. (in German).